Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674780 | SCV000800176 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-05-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000674780 | SCV000893288 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000797378 | SCV000936932 | pathogenic | not provided | 2024-01-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg2323*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 26927203, 29625443). ClinVar contains an entry for this variant (Variation ID: 558501). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000797378 | SCV002762305 | pathogenic | not provided | 2022-11-23 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 26927203, 33302505, 35266249, 30459346, 29625443) |
SN ONGC Dept of Genetics and Molecular biology Vision Research Foundation | RCV003389481 | SCV003927152 | pathogenic | Usher syndrome | 2022-12-31 | criteria provided, single submitter | research | |
Prevention |
RCV004527731 | SCV004111769 | pathogenic | USH2A-related disorder | 2023-02-22 | criteria provided, single submitter | clinical testing | The USH2A c.6967C>T variant is predicted to result in premature protein termination (p.Arg2323*). This variant has been reported in individuals with Usher syndrome or non-syndromic retinitis pigmentosa (Pierrache et al. 2016. PubMed ID: 26927203; Table S3 in Sun et al. 2018. PubMed ID: 29625443; Martín-Sánchez et al. 2020. PubMed ID: 33302505). This variant is reported in 0.0033% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-216138812-G-A). Nonsense variants in USH2A are expected to be pathogenic, and this variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/558501). Given all the evidence, we interpret c.6967C>T (p.Arg2323*) as pathogenic. |
Genome- |
RCV003453389 | SCV004181586 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001829884 | SCV004181587 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003453389 | SCV004208245 | pathogenic | Retinitis pigmentosa 39 | 2023-12-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001829884 | SCV002090869 | pathogenic | Usher syndrome type 2A | 2020-09-02 | no assertion criteria provided | clinical testing |